Clinical Trial Update: Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus [Phase 2]

View source ↗

Summary

A Phase 2 study of daxdilimab (HZN-7734) in participants with discoid lupus erythematosus has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Discoid Lupus Erythematosus

Drugs mentioned

• DAXDILIMAB (daxdilimab)

Snippet

Sponsor: Amgen | Conditions: Discoid Lupus Erythematosus | Phase 2 | Status: TERMINATED